Hofmann Elisa A, Polonsky Kenneth S, Weiss Roy E
Section of Endocrinology, Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA.
Endocr Pract. 2002 Mar-Apr;8(2):113-8. doi: 10.4158/EP.8.2.113.
To describe a case of acromegaly in a young patient with poorly controlled diabetes mellitus and suggest guidelines to distinguish acromegaly and high growth hormone (GH) levels previously reported in poorly controlled type 1 diabetes.
We present a detailed case report, including clinical findings and serial laboratory results in a patient with type 1 diabetes and a GH-secreting pituitary tumor.
A 28-year-old woman with type 1 diabetes underwent assessment for secondary amenorrhea and worsening glycemic control. A low estradiol level and an inappropriately low level of follicle-stimulating hormone prompted magnetic resonance imaging of the head, which demonstrated a pituitary adenoma. Subsequent endocrine investigation revealed a high insulin-like growth factor I (IGF-I) level (849 mg/L; normal range, 122 to 400). The concentration of insulin-like growth factor-binding protein-3 (IGFBP-3) was also elevated (5.5 mg/L; normal range, 2.0 to 4.2). GH levels measured during episodes of spontaneous hyperglycemia (>180 mg/dL) were in the range of 3 to 5 ng/mL and failed to suppress to below 2 ng/mL after a bromocriptine suppression test. The patient underwent transsphenoidal resection of a pituitary tumor, which stained positively for GH by immunohistochemistry. Postoperatively, glycemic control improved, with decreased fluctuations of hypoglycemia and hyperglycemia, despite a decrease in insulin requirements.
This report highlights the difficulty in interpreting GH and IGF-I levels in patients with type 1 diabetes. In addition, a detailed review of the literature suggests that IGFBP-3 measurements may be helpful in confirming the diagnosis of concurrent acromegaly and distinguishing it from high GH levels attributable to poor control of diabetes.
描述一名患有控制不佳的糖尿病的年轻肢端肥大症患者的病例,并提出区分肢端肥大症和先前报道的控制不佳的1型糖尿病患者中高生长激素(GH)水平的指导原则。
我们呈现一份详细的病例报告,包括一名患有1型糖尿病和分泌GH的垂体瘤患者的临床发现及系列实验室检查结果。
一名28岁的1型糖尿病女性因继发性闭经和血糖控制恶化接受评估。低雌二醇水平和不适当的低促卵泡激素水平促使进行头部磁共振成像,结果显示垂体腺瘤。随后的内分泌检查发现胰岛素样生长因子I(IGF-I)水平升高(849 mg/L;正常范围为122至400)。胰岛素样生长因子结合蛋白-3(IGFBP-3)浓度也升高(5.5 mg/L;正常范围为2.0至4.2)。在自发性高血糖发作期间(>180 mg/dL)测得的GH水平在3至5 ng/mL范围内,并且在溴隐亭抑制试验后未能抑制至2 ng/mL以下。该患者接受了垂体瘤经蝶窦切除术,术后免疫组化检测显示肿瘤GH染色呈阳性。术后,尽管胰岛素需求量减少,但血糖控制得到改善,低血糖和高血糖的波动减少。
本报告强调了在解释1型糖尿病患者的GH和IGF-I水平时存在的困难。此外,对文献的详细回顾表明,测量IGFBP-3可能有助于确诊并发的肢端肥大症,并将其与糖尿病控制不佳导致的高GH水平相区分。